Integrated serum pharmacochemistry and network pharmacology validate Qiangli Dingxuan Tablets ameliorates metabolic hypertension via TLR4/MyD88/NF-κ B pathwayOA
Integrated serum pharmacochemistry and network pharmacology validate Qiangli Dingxuan Tablets ameliorates metabolic hypertension via TLR4/MyD88/NF-κ B pathway
Jia-Yue Zhu;Ying-Jie Dong;Ya-Wen Sun;Min-Qiu Lin;Fan Liu;Jie Su;Gui-Yuan Lv;Su-Hong Chen
School of Pharmaceutical Sciences,Zhejiang Chinese Medical University,Hanzhou 310053,ChinaSchool of Pharmaceutical Sciences,Zhejiang Chinese Medical University,Hanzhou 310053,ChinaSchool of Pharmaceutical Sciences,Zhejiang Chinese Medical University,Hanzhou 310053,ChinaSchool of Pharmaceutical Sciences,Zhejiang Chinese Medical University,Hanzhou 310053,ChinaSchool of Pharmaceutical Sciences,Zhejiang Chinese Medical University,Hanzhou 310053,ChinaSchool of Pharmaceutical Sciences,Zhejiang Chinese Medical University,Hanzhou 310053,ChinaSchool of Pharmaceutical Sciences,Zhejiang Chinese Medical University,Hanzhou 310053,ChinaSchool of Pharmaceutical Sciences,Zhejiang Chinese Medical University,Hanzhou 310053,China
metabolic hypertensionModified Qiangli Dingxuan TabletsTLR4/MyD88/NF-κB signaling pathwayserum-absorbed componentsherbal medicine
metabolic hypertensionModified Qiangli Dingxuan TabletsTLR4/MyD88/NF-κB signaling pathwayserum-absorbed componentsherbal medicine
《传统医学研究（英文版）》 2026 (8)
1-14,14
This study was supported by Natural science foundation of Zhejiang province(No.ZCLMS25H2801 to Ying-Jie Dong),Zhejiang Provincial"Vanguard"and"Leading Goose"R&D Tackling Program(No.2025C02183 to Su-Hong Chen),National Natural Science Foundation of China(No.82274134 to Su-Hong Chen and No.82404900 to Ying-Jie Dong),the Key Laboratory of Zhejiang Province(No.2012E10002 to Gui-Yuan Lv).
评论